

December 7, 2023

BSE Limited,  
P J Towers,  
Dalal Street, Mumbai -400001

**Kind Attn.: Mr. Harshad Naik, Deputy Manager, Listing Compliance**

Dear Sir,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – clarification on reported news item in Business Standard**

This is with reference to your e-mail dated December 6, 2023 and in relation to recent news item which appeared in the “www.business-standard.com” dated December 05, 2023 captioned “US regulators inspect Dr Reddy's, other Indian pharma major”.

In this connection, we would like to inform you that the United States Food and Drug Administration (USFDA) has commenced an inspection at our R&D facility in Bachupally, Hyderabad, and outcome of the same would be updated and necessary disclosure will be made with the stock exchanges. We proactively disclose the outcome of every USFDA inspection to the stock exchanges immediately after the end of the inspection. We will notify the stock exchanges at the end of the present USFDA inspection at our R&D centre.

Please note that there is no event/ information with the Company, which require disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), that has not been disclosed to the stock exchanges.

There is no material impact of this reported news item published in Business Standard on the Company.

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information.

Thanking you.

Yours faithfully,  
For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**  
*Company Secretary, Compliance Officer and Head-CSR*